Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma.
Wolfe Z, Friedland JC, Ginn S, Blackham A, Demberger L, Horton M, McIntosh A, Sheikh H, Box J, Knoerzer D, Federowicz B, Stuhlmiller TJ, Shapiro M, Nair S.
Wolfe Z, et al. Among authors: sheikh h.
Melanoma Res. 2022 Aug 1;32(4):295-298. doi: 10.1097/CMR.0000000000000830. Epub 2022 May 12.
Melanoma Res. 2022.
PMID: 35551160
Free PMC article.